Candidozyma auris (Candida auris): responding to an emerging threat to public health, updated guidance for acute healthcare settings
Aired on 31 March 2025
Candidozyma auris (formerly Candida auris) is a rapidly emerging fungal pathogen with a global distribution. The World Health Organization has categorised C. auris as a critical priority fungal pathogen. C. auris can result in invasive infection, colonisation and outbreaks in healthcare settings; management may be complicated by resistance to antifungal agents. In recent years, C. auris has been increasingly detected and associated with significant hospital outbreaks in England. The UK Health Security Agency (UKHSA) is working with NHS England and other partners to mitigate risks to patients and the public and will imminently publish updated guidance for acute healthcare settings.
Hear from subject matter experts in this collaborative webinar by HIS and UKHSA, as they provide an overview of: C. auris emergence in the UK, introduce new guidance for acute healthcare settings, and outline the current approach to risk mitigation.
Panel members:
- Dr Colin Brown, Head of Antimicrobial Resistance & Healthcare Associated Infections and Deputy Director: Epidemic & Emerging Infections, UKHSA
- Dr Ali Abdolrasouli, Principal Clinical Scientist, UKHSA National Mycology Reference Laboratory
- Dr Emma Budd, Principal Scientist (Fungal Epidemiology), UKHSA
-
Dr Mariyam Mirfenderesky, Consultant in Infectious Disease and Medical Microbiology, UKHSA
-
Ms Val Weston, National IPC Nurse Consultant, NHSE
-
Dr James Elston, Consultant in Epidemiology and Public Health, Incident Director (C. auris), UKHSA
- Prof. Mark Wilcox, National Clinical Director for IPC, NHSE
Additional Q&A speakers:
-
Dr Rohini Manuel, Consultant in Public Health Infection and Consultant Microbiologist, UKHSA
-
Dr Trish Mannes, Regional Deputy Director (South East), UKHSA
-
Ms Carole Fry, IPC Strategic Lead, UKHSA
Session Chair:
- Dr Surabhi Taori, Chair, HIS Professional Development Committee
